Therapeutic and Preventative Cancer Vaccines: The Last 30 Years

Meeting Date and Time
-
Location
Virtual via WebEx
Speaker(s)
Olivera (Olja) Finn, Ph.D.
Sponsor(s)
DCP Immunology Interest Group Seminar Series
Research Group
Chemopreventive Agent Development

Date Posted

The NCI Division of Cancer Prevention Immunology Interest Group (DCP IIG) is pleased to announce the launch of a new seminar series focused on cancer prevention, interception, and immuno-oncology. Please join us for the upcoming inaugural seminar.

Speaker

Olja Finn, Ph.D.

The inaugural speaker is Dr. Olivera (Olja) Finn, University of Pittsburgh Distinguished Professor of Immunology and Surgery and Founding Chair of the Department of Immunology, the position she held from 2001 to 2013. After receiving her Ph.D. in Medical Microbiology at Stanford University in 1980 and completing her postdoctoral training in Immuno-oncology there in 1982, Dr. Finn started her research at Duke University and in 1991 moved to the University of Pittsburgh. She gained prominence through her basic and applied research on tumor antigens and cancer vaccines. She has served and currently serves on NCI study sections and was a member of the NCI Board of Scientific Counselors. Dr. Finn is a member of the American Association of Immunologists where she served as President in 2007/2008. She served two terms as Councilor of the International Union of Immunology Societies (IUIS) and was Chair of the IUIS Committee on Gender Equality and Career Development. She is a member of the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC). Dr. Finn received numerous awards, including the AAI Lifetime Achievement Award (2016), the NCI Outstanding Investigator Award (2016), the AACR CIR Lloyd Old Cancer Immunology Prize (2017), and SITC Richard Smalley Award (2019). In 2019 she was inducted into the inaugural class of AAI Distinguished Fellows and in 2022 became a Fellow of the SITC Immuno-Oncology Academy.

Host

Shizuko Sei, M.D.
Co-Chief, Chemopreventive Agent Development

Contact Person

Wosene Asefa
wosene.asefa@nih.gov